First of crop killer's genome sequence available

July 16, 2002

The first draft sequence of a worldwide crop-killing fungus genome has been completed under the joint National Science Foundation (NSF) and U.S. Department of Agriculture Microbial Genome Sequencing Project.

The fungus Magnaporthe grisea causes rice blast disease, which is estimated to destroy annually enough rice to feed more the 60 million people. The fungus was recently recognized by the Centers for Disease Control and Prevention as a potentially significant biological weapon that could be used for agricultural terrorism.

Certain strains of the fungus can attack domesticated grasses such as barley, wheat, pearl millet, and even turf grasses. Rice blast disease, once thought to be confined to only developing nations, has emerged in the United States over the past decade with the widespread introduction of rice as a crop in the South. In the Midwest, golf courses also have been devastated by the disease's attack on cool season grasses.

Previously, rice blast outbreaks were controlled through the application of costly and potentially hazardous chemicals. Genome sequencing will allow scientists to understand the interactions between the fungus and grasses, and identify the mechanisms that regulate infection of a host plant. This knowledge could help scientists discover new ways to prevent fungal crop infection and the spread of rice blast disease.

"This is an important first step toward understanding how this fungus attacks the rice plant," said Patrick Dennis, NSF's microbial genetics program director. "The scientific community needs this information to fill long-standing gaps in our understanding and to develop new strategies for controlling this destructive pathogen. This will be a springboard to new discoveries."

The research is continuing at North Carolina State University and the Whitehead Institute's Center for Genome Research in Massachusetts.
Note to Editors: To view the rice blast genome sequencing data, see:

NSF PR 02-62

Media contact:
Manny Van Pelt

Program contact:
Patrick Dennis

National Science Foundation

Related Genome Sequencing Articles from Brightsurf:

Tracking the SARS-CoV-2 virus with genome sequencing
Dirk Dittmer, PhD, professor of microbiology and immunology at the UNC School of Medicine, is tracking the virus that causes COVID-19 by sequencing the genome of virus samples collected from diagnostic testing.

Genome sequencing accelerates cancer detection
Recent cancer studies have shown that genomic mutations leading to cancer can occur years, or even decades, before a patient is diagnosed.

Whole genome sequencing reveals genetic structural secrets of schizophrenia
UNC School of Medicine scientists have conducted the largest-ever whole genome sequencing study of schizophrenia to provide a more complete picture of the role the human genome plays in this disease.

Using whole-genome sequencing for early identification and containment of AMR pathogens
A study published today examines the evolutionary and epidemiologic history of an epidemic strain of extensively drug-resistant tuberculosis (XDR-TB) -- called LAM4/KZN.

Whole genome sequencing could help save pumas from inbreeding
The first complete genetic sequences of individual mountain lions point the way to better conservation strategies for saving threatened populations of the wild animals.

Researchers move beyond sequencing and create a 3D genome
St. Jude Children's Research Hospital scientists have taken whole genome sequencing to the next level by creating a 3D map of the genome to better understand development and disease.

Clinical utility of rapid whole genome sequencing in neonates with seizures
Clinical utility of rWGS in the evaluation of neonatal seizures.

Viral genome sequencing in the heart of a Lassa outbreak
The first researchers to deploy a mobile nanopore sequencing technology to evaluate viral genomics at the height of a Lassa virus outbreak in 2018 now report their results.

New era for blood transfusions through genome sequencing
In a new study, investigators from Brigham and Women's Hospital and Harvard Medical School, as well as from the New York Blood Center have leveraged the MedSeq Project -- the first randomized trial of whole genome sequencing in healthy adults -- to develop and validate a computer program that can comprehensively and cost-effectively determine differences in individuals' blood types with more than 99 percent accuracy.

Does genome sequencing increase downstream costs?
The MedSeq Project, led by investigators at Brigham Women's Hospital, is the first randomized trial to provide whole genome sequencing to both presumably healthy patients as well as those with a known cardiology issue.

Read More: Genome Sequencing News and Genome Sequencing Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to